X-ray Structures of Human Furin in Complex with Competitive Inhibitors

Sven O. Dahms,*† Kornelia Hardes,‡ Gero L. Becker,‡ Torsten Steinmetzer,‡ Hans Brandstetter,§ and Manuel E. Than*†

†Protein Crystallography Group, Leibniz Institute for Age Research-Fritz Lipmann Institute (FLI), Beutenbergstr. 11, 07745 Jena, Germany
‡Department of Pharmaceutical Chemistry, Philipps University Marburg, Marbacher Weg 6, D-35032 Marburg, Germany
§Department of Molecular Biology, University of Salzburg, Billrothstrasse 11, A-5020 Salzburg, Austria

Supporting Information

ABSTRACT: Furin inhibitors are promising therapeutics for the treatment of cancer and numerous infections caused by bacteria and viruses, including the highly lethal Bacillus anthracis or the pandemic influenza virus. Development and improvement of inhibitors for pharmacological use require a detailed knowledge of the protease’s substrate and inhibitor binding properties. Here we present a novel preparation of human furin and the first crystal structures of this enzyme in complex with noncovalent inhibitors. We show the inhibitor exchange by soaking, allowing the investigation of additional inhibitors and substrate analogues. Thus, our work provides a basis for the rational design of furin inhibitors.

Furin is a member of the pro-hormone/pro-protein convertase family (PCs) of subtilisin-like endopeptidases.1 PCs are required for activation and maturation of many secreted proteins. Target proteins include peptide hormones, growth factors, matrix metalloproteases, blood clotting factors, regulators of the cholesterol metabolism, bacterial toxins, and viral capsid proteins.2,3 Therefore furin and other PCs are intensively investigated as pharmacological targets for the treatment of many diseases, e.g., atherosclerosis, hypercholesterolaemia, and cancer, as well as viral and bacterial infections.1,4 Proteolysis by furin is highly specific and occurs C-terminal to a multibasic recognition motive. The extended substrate binding site gives rise to diverging specificities, strongly favoring arginine at P1 and basic amino acid side chains at P2, P4, and/or P6, whereby R-[X]-(R/K)-R↓ is the most common recognition sequence.

Up to now several compound classes have been identified as promising starting points for drug development. In addition to small molecules and peptide based inhibitors,5 also cameld VHH-antibodies were found to selectively inhibit furin.6 It was shown that furin inhibitors are indeed suitable to prevent the growth and invasiveness of tumors (e.g., refs 7 and 8), the replication of viruses (e.g., refs 9 and 10), or the toxicity of bacterial toxins (e.g., refs 11 and 12). For their broad pharmacological application, next generation compounds require, however, improvements of their stability, selectivity, bioavailability, and/or pharmacokinetics.5

Structure-guided drug design provides the possibility for rational modification and directed development of enhanced inhibitors. This approach requires an in-depth structural understanding of furin—inhibitor complexes. So far, structures of mouse furin13 and of its yeast homologue kexin14 are available only in complex with covalently attached peptides. The mouse furin structure showed the interaction with a prototypical R-V-K-R↓ recognition motive. Investigation of other furin substrate analogues or inhibitors by exchange of the initially co-crystallized compound, however, was not possible.

Peptidomimetic compounds based on a phenylacetyl-Arg-Val-Arg-4-(amidomethyl)benzamidine (Phac-RVR-4-Amb) core structure15 belong to the strongest noncovalent inhibitors available so far. Upon variation of the P5 position, dramatic changes of the Ki values were observed that cannot be explained by the known recognition motive. The Ki improved by approximately 2 orders of magnitude after addition of basic substituents, e.g., by modification of the Phac-moiety at P5 by a m- or p-guanidinomethyl group.15

Here we describe a novel preparation of human furin and two crystal structures of this enzyme in complex with competitive, noncovalent inhibitors. The tight binding observed for the inhibitor complexes is accompanied by a very strong increase of the structural stability in thermal denaturation experiments. The structures explain the different affinities of the

Received: February 4, 2014
Accepted: March 25, 2014
Published: March 25, 2014

dx.doi.org/10.1021/cb500087x | ACS Chem. Biol. 2014, 9, 1113−1118
inhibitors and the related specificity of the protease for substrates with Arg/Lys residues at the P5 position.

We have developed a novel preparation of human furin and solved the first structures of a PC in complex with noncovalent, competitive inhibitors, a prerequisite for the structure based development of next generation compounds. The interaction of the substrate mimetic inhibitor within the active site cleft of furin revealed so far exclusive insights about specificity determinants beyond the S4 pocket.

**Purification and Crystallization.** Successful crystallization of human furin required the development of a novel expression and purification procedure to obtain highly homogeneous protein samples. For this purpose, a minimal, C-terminally 6xHis-tagged construct (Asp23–Ala574) was designed for transient expression in human embryonic kidney cells (HEK293). A specialized HEK293S Gnt− cell line16 was used to produce human furin with homogeneous termini and a uniform glycosylation. An efficient, ∼300-fold enrichment of the active protease from a fetal bovine serum (FBS) rich medium was achieved with a three-step affinity chromatography scheme, including immobilized metal affinity purification (IMAC) and inhibitor based affinity purification17 (Supplementary Figure 1). Typically, 1–2 mg of purified enzyme was obtained per liter of conditioned cell culture medium. The described expression and purification procedure can readily be adapted to the large-scale preparation of other PCs in the future. The herein produced, homogenously glycosylated, recombinant human furin showed inhibition constants very similar to those of the complex glycosylated enzyme used in recombinant human furin showed inhibition constants very similar to those of the complex glycosylated enzyme used in previous studies (Supplementary Table 1; refs 10 and 15).

**Overall Structure.** Furin was crystallized in the presence of m-guanidinomethyl-Phac-RVR-Amba (11, Figure 1a, ref 15). The crystals belong to the orthorhombic spacegroup P212121. The structure of the furin–I1 complex was solved by molecular replacement with mouse furin as search model (PDB-ID 1P8J, ref 13) and refined to 2.3 Å resolution (Figure 1b, Table 1). The asymmetric unit contains six copies of the protease–inhibitor complex arranged in three pairs. The active site of all proteomers is solvent-exposed and allows the exchange of the inhibitor in soaking experiments (see below). All six human furin molecules are nearly identical (∼0.05 Å RMSD of their Ca positions in multiple structural alignments with PDBEntry18). Structural alignments of human and mouse furin revealed average RMSD values of 0.5 Å, showing a high overall similarity for the catalytic domain and P-domain between the homologues. Sites of single amino acid substitutions between the homologues were well-defined in the difference electron density map (Supplementary Figure 2) and do not affect the overall fold. The human structure supports the previously modeled specificity determinants at P1′ and P2′19 and allows to further study, e.g., the structural impact of single nucleotide polymorphisms in furin and other PCs, reported to play a role in diabetes and obesity.20

In addition to the previously described calcium-binding sites 1 and 2 (Ca1, Ca221), further metal-binding sites were identified in the structure of human furin (Figure 1b, Supplementary Figure 3a–c) and validated using CheckMyMetal.22 The newly identified calcium binding site 3 (Ca3) is located at the surface of the protein (Supplementary Figure 3c). It is coordinated by the side chains of Asp174, Asp179 (bidentate), the carbonyl oxygen of Asp181, as well as three solvent molecules and adopts a typical pentagonal bipyramidal arrangement (average bond distance 2.5 Å). Near to the active site cleft we identified a Na+-binding site, indicated by a spherical electron density surrounded by five oxygen atoms, Thr314 OH, Thr314 O, Ser311 O, Thr309 O, and an internal solvent molecule (Supplementary Figure 4; average metal–oxygen distance 2.38 Å). Na1 was also observed in the structure of the yeast homologue kexin.23 The relative position of Na1 with respect to the active site mirrors that found in thrombin and related coagulation proteases.24 This finding points toward another intriguing example of convergent evolution of trypsin- and subtilisin-like serine proteases.25 Interestingly, the metal binding sites Ca1, Ca3, and Na1 of human furin are also found in the catalytic domain of the thermostable subtilisin-like protease thermitase.26

**Competitive Inhibition of Human Furin.** Different from the covalently inactivated PC structures available so far, the catalytic triade of human furin adopts a conformation that shows the residues Ser368 and His194 in tight hydrogen-bonding distance as expected for a respective proton transfer and the nucleophilic attack at the substrate’s scissile peptide bond (Figure 2a). The oxygen-anion hole is occupied by the well-defined water molecule 701, bridging Ser368 and Asn295. Inhibitor I1 contains a C-terminal Amba headgroup at the P1′ position, mimicking the preferred arginine side chain found here for most of the natural furin substrates. Similar to arginine, Amba deeply inserts into the S1 pocket (Supplementary Figure S), forming tight hydrogen bonds with the carboxyl oxygen atoms of Pro256 and Ala292 as well as electrostatic interactions.
with Asp306 (Figure 2a). The Amba group mediates extensive van der Waals interactions, resulting in tight enclosure of the planar phenyl ring by the peptide bonds Ser253—Gly255 on one side and the peptide bonds encompassing Gly294 on the other side (Figure 2a). In addition, the loss of entropy upon fixation to the S1 pocket is expected to be lower for Amba compared to more flexible moieties such as arginine. The tight interactions observed in the structure are in excellent agreement to kinetic studies, showing an increase of the inhibition potency of approximately 2 orders of magnitude, if agreement to kinetic studies, showing an increase of the 

Other side (Figure 2a). In addition, the loss of entropy upon fixation to the S1 pocket is expected to be lower for Amba compared to more flexible moieties such as arginine. The tight interactions observed in the structure are in excellent agreement to kinetic studies, showing an increase of the inhibition potency of approximately 2 orders of magnitude, if agreement to kinetic studies, showing an increase of the

Table 1. Data Collection Statistics

<table>
<thead>
<tr>
<th></th>
<th>I1</th>
<th>I2</th>
</tr>
</thead>
<tbody>
<tr>
<td>data collection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>wavelength (Å)</td>
<td>141.18, 152.85, 168.31</td>
<td>141.62, 152.61, 168.54</td>
</tr>
<tr>
<td>space group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>unit cell parameters a (Å), b (Å), c (Å)</td>
<td>141.18, 152.85, 168.31</td>
<td>141.62, 152.61, 168.54</td>
</tr>
<tr>
<td>resolution range (Å)</td>
<td>50.0–2.3 (2.44–2.30)</td>
<td>50.0–2.7 (2.86–2.7)</td>
</tr>
<tr>
<td>Rwork (%)</td>
<td>7.2 (30.5)</td>
<td>7.9 (28.0)</td>
</tr>
<tr>
<td>Rfree (%)</td>
<td>139 (59.7)</td>
<td>152 (52.6)</td>
</tr>
<tr>
<td>I/IO (%)</td>
<td>9.7 (2.6)</td>
<td>9.7 (2.8)</td>
</tr>
<tr>
<td>completeness (%)</td>
<td>99.4 (98.5)</td>
<td>99.5 (99.0)</td>
</tr>
<tr>
<td>obs: total/unique</td>
<td>610,838/160,915</td>
<td>377,299/100,092</td>
</tr>
<tr>
<td>refinement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rwork/Rfree</td>
<td>18.5/21.6</td>
<td>19.3/21.8</td>
</tr>
<tr>
<td>nonhydrogen atoms</td>
<td>23,098</td>
<td>22,347</td>
</tr>
<tr>
<td>protein/inhibitor/other</td>
<td>21,332/324/1442</td>
<td>21,332/294/721</td>
</tr>
<tr>
<td>B-factors (Å²)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>overall/Wilson plot</td>
<td>26.7/31.4</td>
<td>23.6/26.8</td>
</tr>
<tr>
<td>protein/inhibitor/other</td>
<td>26.6/22.3/29.9</td>
<td>23.7/22.1/22.2</td>
</tr>
<tr>
<td>RMSD bond length (Å)</td>
<td>0.0079</td>
<td>0.0068</td>
</tr>
<tr>
<td>RMSD bonded B-factors (Å²)</td>
<td>2.5</td>
<td>2.0</td>
</tr>
</tbody>
</table>

**Highest resolution shell is given in parentheses. Calculated in SCALA in the resolution ranges (given in Å) 50–2.31 (2.43–2.31) and 50–2.71 (2.86–2.71) for I1 and I2, respectively.**

The unusual S5 and S4 pockets. Additionally, hydrogen bonds are formed to the backbone carbonyl of Val231 and a bound water molecule 715. This water molecule is also found in the unoccupied S5 pocket of the mouse furin-dec-RVKR-chloromethylketone complex (PDB-ID 1P8J, ref 13), interacting with Asp233, Asp236, and the amide of Ala267. This binding mode of the P5 side chain was completely unexpected and was not predicted by any modeling approach so far. In fact, the positively charged P4 and P5 guanidino groups are only approximately 4 Å apart. The strongly negative potential of furin’s substrate binding pocket, however, facilitates charge equalization and thereby permits formation of a strong hydrogen-bonding network. In this way the P4–P5 combination interacts with the shared S4–S5 site of the protease in a key-lock mechanism, without necessity for any conformational rearrangements. Such a binding mode seems possible for any positively charged moiety at P5 that can adapt an extended conformation to interact with Asp236 and Val231 O. Indeed, kinetic studies demonstrated that the length and the conformational flexibility of the P5 substituent strikingly influence the Kᵢ value. Correspondingly, a change of the guanidinomethyl group from the meta to the para position results in similar binding properties with a change of the Kᵢ from 16.7 ± 0.6 pM to 9.7 ± 1.5 pM (Supplementary Table 1). A largely decreased binding strength (Kᵢ = 196 ± 15.2 pM) is observed, however, if a less extended o-guanidinomethyl-Phac moiety is placed at P5.

Inspection of the furin substrate database FurinDB for the occurrence of basic amino acid side chains at P5 revealed a frequency of 0.33, which compares to a frequency of only 0.25 for their occurrence at P6. Interestingly, 93% of the substrates that have arginine or lysine residues at P5 also contain an arginine side chain at P4. Such recognition sequences are found for substrates that are cleaved by furin with high efficiency, e.g., for hemagglutinin of the highly infectious avian influenza virus strain H5N1, or in both self-activation sites inside the furin prodomain. Next we compared the effect of inhibitors on the overall structural stability of human furin by inspection of their melting
temperatures, $T_{m}$, in thermal denaturation assays (Figure 3). Whereas the uninhibited enzyme shows a $T_{m}$ of 54.1 ± 0.1 °C, this value is increased to a $T_{m}$ of 68.0 ± 0.3 °C in the presence of I1. Addition of Phac-RVR-Amba (I2, Figure 4a) that lacks the guanidinomethyl group at P5 resulted in an intermediate melting temperature of 62.5 ± 0.1 °C. These values correlate well with the corresponding $K_{d}$ values, which were determined to be 16.7 ± 0.6 pM and 977 ± 196 pM for I1 and I2, respectively (Supplementary Table 1). Consequently, the interactions at the S5 pocket of the active site contribute largely to a global stabilization of the protease. Interestingly, it has been demonstrated that thermal stability is directly related to the crystallizability of proteins. We hence presume that the stabilizing effect of I1 also largely improved the tendency of human furin to form well-ordered crystals.

**Exchange of the Inhibitor by Soaking.** During the past two decades a number of inhibitors have been developed, targeting furin and other PCs. However, these compounds require improvements in specificity, affinity, pharmacokinetics, or bioavailability for therapeutic use, calling for a detailed understanding of the interactions of the PCs with substrates and inhibitors at their active site cleft. Especially specificity determinants beyond the canonical multibasic recognition sequence from P1 to P4 are poorly understood, although this is a highly promising target region for the development of inhibitors that selectively bind to specific PC family members. Therefore a general applicable procedure for the structural investigation of furin–inhibitor or furin–substrate interactions is highly needed. The crystals of the noncovalent furin–I1 complex described in this study are very well suited for the exchange of I1 in soaking experiments with other inhibitors or substrate analogues, binding to the active site. To demonstrate the general applicability of this approach, we incubated the furin–I1 crystals with I2. Indeed, the electron density at the P5 position disappeared upon treatment of the crystals with excessive amounts of I2, indicating displacement of the initially co-crystallized inhibitor I1 (Figure 4b). Calculation of an isomorphous difference electron density between the data sets collected before and after soaking unambiguously confirmed the replacement of I1 by I2 (Figure 4b). In addition to the guanidinomethyl group no electron density was observed for the phenyl ring of the phenylacetate moiety of I2. The reason for the disappearance of its electron density is most likely a gain of global structural stability upon inhibitor binding by human furin. Melting curves were determined based on the fluorescence of the dye Sypro Orange in dependence on the temperature.

**Figure 3.** Gain of global structural stability upon inhibitor binding by human furin. Melting curves were determined based on the fluorescence of the dye Sypro Orange in dependence on the temperature.

**Figure 2.** Detailed view of the furin–I1 interaction sites. The furin–inhibitor complex is shown in standard orientation as in Figure 1. In the stereo panels the Cα-carbon trace of the protease is given as cartoon representation (yellow). The inhibitor and important residues of furin are shown in dark gray (ball and stick model) and in cyan (stick model), respectively. Selected water molecules are shown as red spheres. Important interactions are highlighted with black dashes. The $F_o – F_c$ difference electron density omit map of the inhibitor (green mesh) is contoured at 3.5 $\sigma$. (a) The S1 pocket of the protease, interacting with the (amidomethyl)benzamidine-P1 moiety of I1. Ca$^{2+}$ II at the bottom of the S1 pocket is shown as a green sphere. (b) The P2- and the P3-residues of the inhibitor. (c) Interactions of the P4-residue and of the P5-m-guanidinomethyl-phenylacetyl moiety of I1.

$\text{dx.doi.org/10.1021/cb500087x}$
In this work we showed a novel strategy to purify and crystallize a PC in complex with a noncovalent inhibitor. On the basis of these crystals the structural investigation of many other inhibitor–furin complexes is possible by competitive soaking. This strategy will allow the structure guided development of compounds that are highly promising therapeutics for the treatment of cancer as well as of many viral and bacterial infections.2–4

**METHODS**

The coding sequence of human furin was inserted into the plasmid pHLSec38 and expressed by transient transfection of human embryonic kidney cells. The protein was purified in a three-step chromatography scheme, employing metal affinity chromatography, inhibitor based affinity chromatography,37 and size exclusion chromatography. Finally a ~300-fold enrichment of human furin was observed, corresponding to a specific activity of 57 ± 1 u. One unit corresponds to 1 pmol AMC (h × mg)−1 released from the peptide pGlu-Arg-Thr-Lys-Arg-AMC (200 µM) at 37 °C in 100 mM Hepes, pH 7.0, 5 mM CaCl2, 0.5% (v/v) TritonX-100. Details of the expression, preparation, kinetic analyses, and thermal denaturation assays are described in Supporting Information.

For crystallization furin was concentrated to 140–150 µM (~7.5 mg mL−1), and I1 was added to a final concentration of 290 µM. Crystals were grown at 30 °C in 50 mM Tris, pH 8.5, 2.8 M sodium formate and 0.015 mM Cymal-7. For the structural investigation of the complex of furin with I2, crystals were soaked in crystallization solution supplemented with 3 mM I2. Diffraction data were collected at 100 K at the BESSY-II beamline 14.1 of the Helmholtz-Zentrum Berlin (HZB)29 and processed with XDS (v.03/201330). Model building was carried out in COOT (v.0.6.231). CNS (v.1.32) was used for refinement of the structures of furin in complex with I1 and I2 up to 2.3 and 2.7 Å resolution, respectively.

**ASSOCIATED CONTENT**

Supporting Information

Supplementary figures, supplementary tables, and supplementary methods, containing a detailed description of the expression procedure, crystallographic work, enzymatic tests, and thermal denaturation assays. This material is available free of charge via the Internet at http://pubs.acs.org.

**Accession Codes**

Structure factors and coordinates for the complex structures of human furin in complex with inhibitor I1 and I2 have been deposited to the protein databank (PDB) with the accession codes 4OMC and 4OMD, respectively.

**AUTHOR INFORMATION**

**Corresponding Author**

*E-mail: than@fl-leibniz.de.

**Notes**

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

We acknowledge the Helmholtz Zentrum Berlin BESSY II for provision of synchrotron radiation at the beamline BL 14.1 and thank the scientific staff for assistance. This work was supported by EMBO (to S.O.D., ASTF 513 - 2011).

**REFERENCES**


Figure 4. Exchange of the co-crystallized inhibitor I1 by soaking with I2. (a) Phenylacetyl-Arg-Val-Arg-(amidomethyl)benzamidine (Phac-RVR-Arg, I1). (b) Stereo representation of the solvent-accessible surface of the active site cleft of human furin, colored by the electrostatic potential. Inhibitor I2 is shown in standard orientation and is given as a ball and stick model in gray. The residues of the inhibitor are numbered (P1–P5). The Fo − Fc difference electron density map of I2 (blue mesh) is contoured at 3.5 σ. The Fo+I − Fc+I isomorphous difference electron density map (yellow mesh) is contoured at 5 σ.
characterization of non-competitive furin-inhibiting nanobodies. Biochem. J. 448, 73–82.


